^
    14d
    System biology analysis of miRNA-gene interaction network reveals novel drug targets in breast cancer. (PubMed, Nucleosides Nucleotides Nucleic Acids)
    By searching for potential drugs in Drugbank database, we have identified four candidates (phenethyl isothiocyanate, amuvatinib, theophylline, trifluridine) for targeting these genes. In conclusion, we believe that these drugs and their analogs could be used in the targeted therapy of breast cancer in the future.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • MIR127 (MicroRNA 127)
    |
    amuvatinib (MP470)
    1year
    Identification of a cancer-associated fibroblast classifier for predicting prognosis and therapeutic response in lung squamous cell carcinoma. (PubMed, Medicine (Baltimore))
    In silico drug screening identified 6 effective compounds for high-risk CAFs-related LUSC: TAK-715, GW 441756, OSU-03012, MP470, FH535, and KIN001-266. Additionally, search tool for interaction of chemicals database highlighted PI3K-Akt signaling as a potential target pathway for high-risk CAFs-related LUSC. Overall, our findings provide a molecular classifier for high-risk CAFs-related LUSC and suggest that treatment with PI3K-Akt signaling inhibitors could benefit these patients.
    Journal • IO biomarker
    |
    PDGFA (Platelet Derived Growth Factor Subunit A) • SERPINE1 (Serpin Family E Member 1) • SMAD7 (SMAD Family Member 7) • KLF10 (Kruppel Like Factor 10)
    |
    GW441756 • amuvatinib (MP470) • AR-12
    over1year
    Probing the Potential of Defense Response-Associated Genes for Predicting the Progression, Prognosis, and Immune Microenvironment of Osteosarcoma. (PubMed, Cancers (Basel))
    This study elucidated the role and mechanism of BNIP3, PTGIS, and ZYX in OS progression and was well verified by the experimental results, enabling reliable prognostic means and treatment strategies to be proposed for OS patients.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    TGX-221 • amuvatinib (MP470)
    almost2years
    Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma. (PubMed, J Bone Oncol)
    Additionally, we obtained three potentially effective drugs for OS: erlotinib, MP470, and WH-4-023 targeting the PI3K-Akt pathway. The expression level of ZNF37BP was significantly elevated in OS cell lines than in normal osteoblast hFOB1.19 cells, and that of ATP7A, LIPT1, AL353759.1, and AC005034.5 were decreased considerably in OS cell lines. Cuproptosis-related lncRNAs are correlated with the CAFs of osteosarcoma, and this could serve as a foundation for OS survival prediction and treatment.
    Journal
    |
    CD4 (CD4 Molecule) • ATP7A (ATPase Copper Transporting Alpha) • LIPT1 (Lipoyltransferase 1)
    |
    erlotinib • amuvatinib (MP470)
    almost4years
    Late p65 nuclear translocation in glioblastoma cells indicates non-canonical TLR4 signaling and activation of DNA repair genes. (PubMed, Sci Rep)
    Moreover, an increased apoptotic rate was observed when the GBM-derived U87MG cells were co-treated with LPS and Temozolomide (TMZ) in comparison to TMZ alone. Moreover, the combined treatment with the RAD51 inhibitor, Amuvatinib in combination with, TMZ after LPS stimulation reduced tumor cell viability more than with each treatment alone. In conclusion, our results suggest that stimulation of TLR4 combined with pharmacological inhibition of the DNA repair pathway may be an alternative treatment for GBM patients.
    Journal • IO biomarker
    |
    RAD51 (RAD51 Homolog A) • TLR4 (Toll Like Receptor 4)
    |
    temozolomide • amuvatinib (MP470)